A derivative of a GLP-1 analogue of the general Formula I: Xaa 7 -Xaa 8 -Glu-Gly-Thr-Xaa 12 -Thr-Ser-Asp-Xaa 16 -Ser-Xaa 18 -Xaa 19 -Xaa 20 -Glu-Xaa 22 -Xaa 23 -Ala-Xaa 25 -Xaa 26 -Xaa 27 -Phe-Ile-Xaa 30 -Xaa 31 -Leu-Xaa 33 -Xaa 34 -Xaa 35 -Xaa 36 -Xaa 37 -Xaa 38, wherein Xaa 7 is L-histidine or deamino-histidine; Xaa 8 is Aib; Xaa 12 is Phe; Xaa 16 is Val; Xaa 18 is Ser; Xaa 19 is Tyr; Xaa 20 is Leu; Xaa 22 is Glu; Xaa 23 is Gln; Xaa 25 is Ala; Xaa 26 is Arg; Xaa 27 is Glu; Xaa 30 is Ala or Glu; Xaa 31 is Trp; Xaa 33 is Val; Xaa 34 is Arg or Lys; Xaa 35 is Gly or Lys; Xaa 36 is Arg or Lys; Xaa 37 is Pro or Lys; Xaa 38 is Lys or absent; wherein at least one of Xaa 34, Xaa 35, Xaa 36, Xaa 37, and Xaa 38 is Lys; and wherein the GLP-1 analogue has a maximum of 6 amino acid changes as compared to the sequence of GLP-1 (SEQ ID NO: 1); which derivative comprises a side chain that is attached to the Lys residue of Xaa 34, Xaa 35, Xaa 36, Xaa 37, or Xaa 38; which side chain comprises: (i) a Branched linker of formula Chem. 11 wherein w is an integer in the range of 0-2; (ii) a 1 st and a 2 nd Protractor selected from Chem. 12, Chem. 12a, and Chem. 13: and and (iii) at least one Linker element-1 of Chem. 1: wherein k is an integer in the range of 1-23, and n is an integer in the range of 1-5; wherein the Branched linker is connected a) at its -CO end to the epsilon amino group of the Lys residue of Xaa 34, Xaa 35, Xaa 36, Xaa 37, or Xaa 38, via an optional Pre-linker, and b) at each of its two -NH ends to the -CO end of each of the 1 st and 2 nd Protractor, respectively, via a 1 st and a 2 nd Post-linker, respectively; and wherein if the Pre-linker is present it comprises the Linker element-1, or if the Pre-linker is absent, each of the 1 st Post-linker and the 2 nd Post-linker comprises the Linker element-1; or a pharmaceutically acceptable salt, amide, or ester thereof. Xaa 7 -Xaa 8 -Glu-Gly-Thr-Xaa 12 -Thr-Ser-Asp-Xaa 16 -Ser-Xaa 18 -Xaa 19 -Xaa 20 -Glu-Xaa 22 -Xaa 23 -Ala-Xaa 25 -Xaa 26 -Xaa 27 -Phe-Ile-Xaa 30 -Xaa 31 -Leu-Xaa 33 -Xaa 34 -Xaa 35 -Xaa 36 -Xaa 37 -Xaa 38, wherein Xaa 7 is L-histidine or deamino-histidine; Xaa 8 is Aib; Xaa 12 is Phe; Xaa 16 is Val; Xaa 18 is Ser; Xaa 19 is Tyr; Xaa 20 is Leu; Xaa 22 is Glu; Xaa 23 is Gln; Xaa 25 is Ala; Xaa 26 is Arg; Xaa 27 is Glu; Xaa 30 is Ala or Glu; Xaa 31 is Trp; Xaa 33 is Val; Xaa 34 is Arg or Lys; Xaa 35 is Gly or Lys; Xaa 36 is Arg or Lys; Xaa 37 is Pro or Lys; Xaa 38 is Lys or absent; wherein at least one of Xaa 34, Xaa 35, Xaa 36, Xaa 37, and Xaa 38 is Lys; and wherein the GLP-1 analogue has a maximum of 6 amino acid changes as compared to the sequence of GLP-1 (SEQ ID NO: 1); (i) a Branched linker of formula Chem. 11 wherein w is an integer in the range of 0-2; (ii) a 1 st and a 2 nd Protractor selected from Chem. 12, Chem. 12a, and Chem. 13: and and (iii) at least one Linker element-1 of Chem. 1: a) at its -CO end to the epsilon amino group of the Lys residue of Xaa 34, Xaa 35, Xaa 36, Xaa 37, or Xaa 38, via an optional Pre-linker, and b) at each of its two -NH ends to the -CO end of each of the 1 st and 2 nd Protractor, respectively, via a 1 st and a 2 nd Post-linker, respectively; and if the Pre-linker is present it comprises the Linker element-1, or if the Pre-linker is absent, each of the 1 st Post-linker and the 2 nd Post-linker comprises the Linker element-1;